Request FREE:
Stock market calendar 2023 as a wall poster!
“We found that using the vaccine reduced the risk of confirmed severe RSV disease by almost 84 percent,” said Paul Burton, chief medical officer at Modern, the German Press Agency. The effectiveness of the vaccine once morest RSV-related diseases of the lower respiratory tract with two or more symptoms was examined. The safety profile was also very good. According to the company, around 37,000 people aged 60 and over from 22 countries took part in the study.
The so-called messenger RNA (messenger ribonucleic acid, mRNA) became known to a broad public through its use in the corona vaccines. The mRNA in vaccines delivers part of the genetic information of the virus to human cells. With this information, they produce a protein of the pathogen once morest which the body then develops defense reactions. In later contact with the pathogen, the immune system recognizes the protein and can fight the virus faster and more specifically.
“In this vaccine, we encapsulate this messenger RNA in the same lipid that we use for the Covid vaccine, which is used in hundreds of millions of people around the world,” Burton said.
The vaccine developed is initially intended for people aged 60 and over. However, RSV can also be particularly dangerous for infants and young children. Research is also being done on this Modernsaid Burton. “We have five other ongoing programs for young children, pregnant mothers and a number of other population groups. We will also publish this data in the coming months.”/wem/DP/stw
Source: dpa-AFX
